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Abstract
Chronic hepatitis B virus (HBV) infection in endemic areas usually starts since infancy and early childhood and
persists lifelong. The clinical course varies among different chronic infected subjects. Majority of chronic HBV
infected children present with immune-tolerant status initially, experience the immune clearance phase with
various degree of liver injury during or beyond puberty, and then enter the inactive phase after hepatitis B e
antigen (HBeAg) seroconversion. Part of them may have HBV DNA titers elevation with hepatitis flare after HBeAg
seroconversion, the so call HBeAg-negative hepatitis flare. Liver cirrhosis, and even hepatocellular carcinoma may
develop afterward.
The complex course of chronic HBV infection is associated with the age/route of viral acquisition, host factors
such as immune and endocrine factors, viral factors, and host-viral interactions. The adrenarche and puberty
onset modulate the start of immune clearance and the severity of liver inflammation in chronic HBV infected
children. The genotype and phenotype of human cytokines, innate immunity, and human leukocyte antigens are
also associated with the onset of immune clearance of HBV and severity of inflammation. Immune escape HBV
mutant strains, emerged during the immune clearance phase under host immune surveillance, may cause different
impacts on viral biosynthesis, host immune responses, and clinical course.
Early events in childhood during chronic HBV infection may serve as important predictors for the later outcome
in adulthood. Understanding the mechanisms triggering liver inflammation and their long-term impacts may
enhance the development of better and earlier therapeutic strategies for patients with chronic HBV infection.
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Introduction
Human hepatitis B virus (HBV) is a member of hepadna-
virus, a small enveloped virus with partially double stranded
circular deoxyribonucleic acid (DNA) that replicate by re-
verse transcription [1]. The virus particles deliver their
DNA into the hepatocyte nucleus at the time of infection,
where the viral DNA is then converted to a covalently
closed circular DNA (cccDNA) that serve as the transcrip-
tional template for pre-genomic ribonucleic acid (RNA)
and messenger RNA (mRNA) for hepatitis B surface
antigen (HBsAg), hepatitis B e antigen/core antigen
(HBeAg/HBcAg), polymerase, and X protein (HBx) [2].
HBV infection is the major pathogen causing chronic
hepatitis, liver cirrhosis, and hepatocellular carcinoma
(HCC) in the world [3]. The clinical course of HBV in-
fection is diverse among individuals with different host
genome, viral strains, and host-viral interactions. The
earlier the HBV acquisition age is, the more likely the
lifelong infection results [4–6]. In endemic areas, such
as Taiwan, perinatal infection account for approximately
half of the cases of chronic HBV infection before the
universal HBV vaccination program, and the perinatal
infection increased to 90 % after the program [7]. The
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natural course of chronic HBV infection was generally
sub-divided into immune-tolerant, immune clearance/
inflammatory, post HBeAg seroconversion inactive phases.
Part of the infected subjects may enter the HBeAg-negative
hepatitis reactivation phase, and even develop liver cirrhosis
or HCC [8, 9]. Very minority of chronic HBV infected sub-
jects may developed HBsAg seroconversion, and get rid off
chronic infected status. The immune-tolerant phase is indi-
cated by normal alanine aminotransferase (ALT) levels,
high viral loads, and presence of HBeAg. In majority of the
patients during or after the adolescent stage, the flare of
ALT and the HBeAg seroconversion to its antibody (Anti-
HBe) indicate the immune clearance/inflammatory phase.
HBeAg seroconversion generally indicates the decrement of
active viral replication and hepatitis activity, while delayed
HBeAg seroconversion with persistently high viremia after
the 4th decade of life indicates a higher risk of developing
liver cirrhosis, and HCC [10–14]. Chronic HBV infected
subjects usually experience the inactive phases with normal
ALT levels, low viremia and negative HBeAg after HBeAg
seroconversion. However, up to 10-25 % of chronic HBV
infected adults subjects may suffer from HBeAg-negative
hepatitis flare after HBeAg seroconversion, especially in
those who experience late HBeAg seroconversion, and are
associated with increased life-long risk of liver cirrhosis and
HCC [13, 14]. HBV basal core promoter (BCP) and pre-
core/core gene mutation emerge during the process of im-
mune clearance phase and HBeAg seroconversion, and are
associated with different viral replication ability and clinical
outcomes [15, 16].
The triggering host and viral factors to end the im-
mune-tolerant phase, modulating the course of immune-
clearance/inflammatory phase, HBeAg/HBsAg seroclear-
ance and seroconversion, and even the occurrence of
HBeAg-negative hepatitis flare are the key determinants to
the life-long risk of liver injuries, liver cirrhosis and HCC.
Review
Host factors
Clinical relevanxce of human endocrine influence
From a very long-term chronic HBV cohort followed from
infants and young children to adult life, the spontaneous
HBeAg seroconversion rate was low before 10 years of age,
and accelerated since the second decade of life [17]. The
annual spontaneous HBeAg seroconversion rate was 1.70 %
(95 % CI 0.43 %–2.97 %) in the first decade of life, 3.78 %
(95 % CI 2.61 %–4.94 %) in the second decade of life, and
4.02 % (95 % CI 1.61 %–6.23 %) in the third decade of life
in genotype B and C chronic HBV infected cohort [17].
Majority of children with chronic HBV infection entered
the immune clearance/inflammatory phase after their pu-
berty onset [17, 18]. Earlier onset of puberty and increased
steroid 5-alpha reductase type II (SRD5A2) enzyme activity
are associated with earlier HBeAg seroconversion in males
with chronic HBV infection [19]. Earlier menarche, in-
dicating earlier puberty-onset, is also associated with
earlier HBeAg seroconversion in female subjects with
chronic HBV infection [20].
The clinical courses of infection with various pathogens
differ greatly between males and females; the difference is
thought to result from cross-talk between different sex
steroids and immune effectors [21, 22]. The main sex ste-
roids at puberty are testosterone and estradiol in male and
female subjects, respectively. Animal studies showed the
androgen pathway can increase HBV transcription and
suppress the tumor suppressor gene in early hepatocarci-
nogenesis [23, 24], the estrogen pathway can repress HBV
genes’ transcription [25]. Hence, the association of puberty
onset in both genders with the start of immune clearance/
inflammation may not be answered by the sex steroids
alone [19, 20]. Factors other than sex steroids and common
to both genders, acting during the peri-puberty period, may
contribute to the initiation of immune clearance/inflamma-
tory phase.
Dehydroepiandrosterone sulphate (DHEAS), a adrenarche
marker, elevated 2-3 years before puberty is significantly
associated with the age of HBeAg seroconversion in
both genders [26]. DHEAS is elevated between six and
eight years of age in both genders and peaks at the third
decade of life [27, 28]. It is regarded as a potent immune
modulator in human immune responses to various infec-
tious pathogens [27–31]. Higher serum DHEAS levels at
mid-puberty was further showed to predict higher decay
rate of HBV viral load and HBsAg titer from mid-puberty
to young adulthood [26].
The endocrine factors, particularly the DHEAS, may
be partially responsible for the initiation of immune
clearance and inflammation in immune-tolerant subjects
with chronic HBV infection (Fig. 1).
Clinical relevance of human immune system
Host immune response is considered to play an important
role in the course of HBV infection. Human T-lymphocytes
may identify HBV viral peptides presented by human
leukocyte antigen (HLA) on antigen presenting cells.
Variations in immune response are often associated with
polymorphisms of HLA antigens [32]. Previous cross sec-
tion studies in Gambia showed major histocompatibility
complex (MHC) class II alleles HLA-DRB1*1301-02 are
associated with protection against persistent HBV infec-
tion, and subsequently confirmed by other two series in
Germany and Korea. [33–35] Other series suggested a
protective role of HLA-DR2, HLA-DR*0406, HLA-B*4001,
and HLA-DR7 antigens for acute HBV infection [36, 37].
Recent genome-wide association cross-sectional study
showed the association of HLA-DP with protection against
chronic hepatitis B and with viral clearance in Japanese and
Korean [38]. Our long-term cohort showed the HLA
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class I antigen B61 and class II antigen DQB1*0503
are associated with earlier HBeAg seroconversion in
Taiwanese children with chronic HBV infection [39].
Cytokines play important roles in the defense mechan-
ism directly by inhibiting viral replication and indirectly
by determining the predominant pattern of host immune
response, which is regulated by human genetic background
and modulates outcomes of chronic viral hepatitis. Previous
study showed interferon-γ and tumor necrosis factor-α
(TNF-α) may contribute to the cell mediated anti-HBV re-
sponse in children with chronic HBV infection entering the
immune clearance/inflammatory phase [40, 41].
Our candidate gene approach analysis in a long-term
HBV cohort, demonstrated that interleukin (IL)-10 and
IL-12 correlate with the HBeAg seroconversion age and
severity of inflammation during the immune clearance/
inflammatory phase. IL-10 -1082 G/G genotype is as-
sociated with higher serum IL-10 levels, while the IL-
12β -10993 C/G genotype is associated with higher
HBcAg inducible IL-12 secretion of peripheral blood
mononuclear cells. Both are associated with earlier
spontaneous HBeAg seroconversion [42].
Increasing evidences indicate that innate immune re-
sponses, especially the toll-like receptor (TLR) signaling
pathway, are essential to the defense mechanism against
various pathogens, including HBV, by activating down-
stream inflammatory cascades like nuclear factor κB,
interferon regulatory factor, mitogen activated protein
kinases, and pro-inflammatory cytokines [43, 44].
Chronic HBV infected patients with TLR5 rs5744174
(p.Phe616Leu) and C allele at TLR9 rs5743836 promoter
area polymorphism are also noted to have earlier spon-
taneous HBeAg seroconversion [43]. TLR5 rs5744174
(p.Phe616Leu) associated with higher interferon-γ pro-
duction in chronic HBV infected patients, and C allele at
the TLR9 rs5743836 promoter SNP site was reported to
increase TLR9 receptor expression levels, which may
mediate stronger signals from thymosin α-1 to suppress
HBV replication through downstream cytokines [43].
The A-allele of IL-10 SNP rs1800872, and the G-allele
of IL-12β SNP rs3212217 were predictors of spontaneous
HBsAg seroconversion and HBV recovery in HBV in-
fected patients [45]. In human liver tissue, IL-10 and
IL-12β mRNA abundances were positively correlated
with interferon-γ mRNA expression levels during the
immune clearance/inflammatory phase [46]. The G allele
carriers at TLR4 rs4986790 (p.Asp299Gly) was demon-
strated to associate with spontaneous HBsAg seroconver-
sion in our cohort. A recent animal study demonstrated
that the TLR4-dependent pathway altered the gut micro-
biota in mice and stimulated liver immune response and
resulted in rapid HBV clearance [43, 47].
The interferon-γ mRNA abundance in human liver
was also associated with lower furin, and higher program
death 1 (PD-1)/program death ligand -1 (PD-L1)
mRNA levels in liver tissue from HBeAg-positive pa-
tients [45, 46]. The intra-hepatic interferon-γ may
modulate the inflammatory response to avoid exces-
sive hepatocyte damage through the enhancement of
PD-1 and PD-L1 expression, whereas interferon-γ me-
diated furin suppression may contribute to a reduc-
tion in HBeAg and HBsAg biosynthesis [45–49].
Fig. 1 Fine tune interactions between the host and hepatitis B virus (HBV) during the chronic natural course of infection. CTL = cytotoxic T lymphocyte;
HLA = human leukocyte antigen; IL = interleukin; IFN = interferon; NK = natural killer cell; PD-1 = program death – 1; PD-L1 = program death ligand-1;
TLR = toll like receptor
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These evidences implied both the innate immune fac-
tors and human cytokine may modulate the interferon-γ
mediated HBV suppression pathway to promote earlier
HBeAg seroconversion, and clear the HBV in human.
Viral factors
Clinical relevance of HBV genotype and viral mutants
emerging during immune clearance/inflammatory phase,
and viremia profile
Different HBV genotypes have been documented to be
an important predictor of the clinical course of chronic
HBV infection. Chronic genotype D HBV was reported
to associate with more severe liver damage than genotype
A HBV, and predict HCC in India [50]. Genotype B and C
are the predominant HBV strains in far-eastern Asian
countries, while the genotype C is noted to associate with
more severe liver disease and delayed spontaneous HBeAg
seroconversion than genotype genotype B HBV in both
adults and children in Taiwan [51, 52]. The genotype Ba
HBV was reported to associate with the development of
HCC in young non-cirrhotic patients in Taiwan, while
the genotype Bj HBV does not shown to associate with
increased HCC risk as compared with genotype C HBV
infection in Japan [51–53].
In our pediatric HBV cohort followed since immune-
tolerant phase, mutations of core promoter at nucleotide
position 1752, 1775, and 1799 have significant correlations
with HBeAg seroconversion; precore 1896 mutant existed
in half of childhood HBeAg seroconverters; and genotype C
HBV is associated with basal core promotor (BCP) 1762 +
1764 mutations during the process of HBeAg seroconver-
sion [54]. The prevalence of HBV precore/core mutation
strains increased significantly in the immune clearance/in-
flammatory phase than in the immune-tolerant phase [55].
The increased proportion of BCP mutant strain were re-
ported to increase the risk of liver cirrhosis and HCC in
chronic genotype B and C HBV infected adults [56, 57]. A
recent quantitative analysis of precore G1896A and BCP
mutants in interferon-treated patients demonstrated
that the distinct HBV evolution/mutation patterns during
HBeAg seroconversion may present with different HBV
viremia pattern after HBeAg seroconversion [58].
Young HBeAg seroconverters in a pediatric cohort
showed decreased viral loads, persistent normal ALT
levels, and uneventful courses after HBeAg seroconversion
[59]. However, HBeAg seroconversion beyond the 4th
decade of life in adults is associated with increased risk
of increased HBV viral load, HBeAg-negative hepatitis
flare, liver cirrhosis and HCC [13, 14, 60]. These evidences
implied that, different immune mechanism and possible
different HBV mutants selected during the immune clear-
ance/inflammatory phase between young and old HBeAg
seroconverters may results in different clinical courses and
life-long outcomes.
Host-virus interaction
Clinical relevance of host and virus interaction
Gender is a key determinant of chronic HBV clinical
outcome, and the relative risk of HBV-related HCC and
liver disease related death are consistently several
fold (1.5 to 7.6 times) higher in males than females
[61–63]. Animal studies showed the androgen path-
way can increase HBV transcription, while the estro-
gen pathway may repress the efficacy of HBV genes
transcription [23–25]. Our previous study also dem-
onstrated the severity of liver inflammation is closely
associated with the serum testosterone levels in
chronic HBV infected males [19]. The different out-
comes between chronic HBV infected males and fe-
males are closely related to the effect of sex steroids
on HBV biosynthesis.
Furin, a proprotein peptidase located at the endoplasmic
reticulum membrane in human hepatocytes, is used
by HBV to facilitate the biosynthesis and maturation
of HBeAg from 25-kDa proprotein to 17-kDa mature
HBeAg [64]. The inhibition of furin either by the
interferon-γ, small molecular weight antagonist and even
the knock-down experiment, were all demonstrated to
inhibit the biosynthesis of mature HBeAg both in vivo
and in vitro studies [46, 64, 65].
PD-1 and PD-L1 are considered as markers of immuno-
logic tolerance and T-cell dysfunction in the presence of
infectious pathogens, including HBV [66, 67]. Blockage of
PD-1/PD-L1 was found to enhance the re-activation of
HBV-specific cytotoxic T lymphocytes (CTLs) and secre-
tion of interferon-γ by circulating intrahepatic lympho-
cytes in subjects with chronic HBV infection and HBeAg
seroconversion [68]. Strikingly, the non-expression of the
PD-1/PD-L1 pathway was associated with fulminant hep-
atic failure in acute HBV-infected patients [69]. Hence, the
up-regulation of the PD-1/PD-L1 pathway may efficiently
mitigate pathogenic T-cell responses, limit liver damage,
and avoid massive hepatocyte damage and fulminate hep-
atic failure in patients with HBV infection [68, 69]. PD-1/
PD-L1, induced in the liver, is thus considered to play key
regulatory roles in avoiding excessive tissue damage when
the inflammatory response is programed to turn off or the
immune response fails to clear the pathogen [46, 48, 70].
Most patients with chronic HBV infection may experience
hepatitis flare-up at the immune clearance/inflammatory
phase, followed by an inactive phase after HBeAg serocon-
version, with a decline in viral load and normalization
of liver-function profile. The interferon-γ mediated circus,
including the up-regulation of PD-1/PD-L1 and down-
regulation of furin, may serve important roles on transition
from cytolytic to non-cytolytic HBV suppression inside the
liver to avoid excessive liver damage and hepatic failure
(Fig. 1) [46]. The interaction between host factors and virus,
both directly on the viral biosynthesis or immune selection
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pressure, play significant roles on the life-long risk of
chronic HBV infected patients.
HBV precore/core gene mutations during the immune
clearance/inflammatory phase are known to be the result
of host immune selection pressure [15, 71]. Mutations in
the HBV precore/core gene may change the amino acid
sequence, protein structure, antigenicity, and the biological
function of both HBeAg and HBcAg. The alternation of
HBcAg sequence and structure may change the stability
of HBV nucleocapsid, HBV pgRNA packaging, and the
efficacy and accuracy of HBV replication [72, 73]. Our
previous study showed the IL-10 -1082 polymorphism site
G/G genotype carrying subjects is associated with higher
HBV C2189A mutations during the immune clearance/
inflammatory phase, and results in lower HBV viral load
[55]. The HBV core protein P135Q mutant and the pre-
core 1896 mutant were the most prevalent mutants before
HBeAg seroconversion in genotype B and C HBV chronic
infected subjects [55, 74]. The HBV P135Q mutant strain
was further demonstrated to altered the normal HBV
capsid assembly, HBeAg biosynthesis, and reduced human
immune responses following HBeAg seroconversion [74].
Hence, different immune selection pressure in different
host results in divergent HBV immune escape mutant
strains, which leads to different viral life cycle and clinical
course/outcomes of chronic HBV infection.
Significance of childhood events on the life-long chronic
HBV disease course
The HBeAg seroconversion age and the severity of liver
damage during the immune clearance phase are both
important outcome determine factors during the natural
course of chronic HBV infection [75]. Extremely early
HBeAg seroconversion before 3 years of age with severe
liver damage was noted to increase the risk of child-
hood HCC [76, 77]. On the other hand, HBeAg serocon-
version during childhood without severe liver damage
have been demonstrated to associate with a relatively un-
eventful course with low viremia profile, lower incidence
of hepatitis reactivation after HBeAg seroconversion, and
higher chance of spontaneous HBsAg seroconversion [45,
59, 75]. Furthermore, the delay in HBeAg seroconversion
Table 1 Host and viral factors associated with the natural
course of chronic hepatitis B virus (HBV) infection
Clinical events Associate factors References
Hepatitis B e antigen
(HBeAg) seroconversion
Host factors
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after the 4th decade of life was regarded as an important
risk factors of HBeAg-negative hepatitis falre, liver cir-
rhosis, and HCC [10–12, 14, 75]. Recently, we demon-
strated earlier breakthrough of immune-tolerance and
earlier HBeAg seroconversion in children with chronic
HBV infection are both important predictors of spon-
taneous HBsAg seroconversion [45].
Conclusions
HBV infection in endemic area mostly occurred in infant
and young childhood, and resulted in chronic infection
status. The viral factors, host factors, and host-virus inter-
actions performed as an orchestra, and acting together to
modulate the natural course of chronic HBV infection
(Table 1). The early events of chronic HBV infection oc-
curring during childhood, reflecting the complex interac-
tions between the host and virus, are key earlier predictors
of the life-long outcomes of chronic HBV infection. Careful
monitoring of host and viral markers, and providing early
and effective intervention may improve the long-term
outcome of chronic HBV infected patients.
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